This article is more than 5 years old. Information may no longer be current.
Upcoming congress highlights cardiometabolic disease prevention, management
Experts across the spectrum of CVD, diabetes and obesity will come together at the 12th annual Cardiometabolic Health Congress to discuss the evolving science and clinical practice advances in the prevention and management of cardiometabolic diseases.
The 3-day meeting will take place from Oct. 4 to 7 at the Boston Sheraton Hotel. Sessions focused on the business of medicine are scheduled on Oct. 4.
More than one-third of the population has at least one cardiometabolic risk factor, including CHD, diabetes, dyslipidemia, hypertension and/or obesity. Preventing and managing cardiometabolic diseases requires a multidisciplinary team. The Cardiometabolic Health Congress (CMHC) 2017 agenda targets a broad range of health care professionals, including cardiologists, endocrinologists, primary care physicians, internal medicine physicians, nurse practitioners, physician assistants and dietitians, among others.
“The predominant audience is what I’d call a sophisticated audience of physicians and health care professionals,” CMHC co-chair Robert H. Eckel, MD, professor of medicine in the division of cardiology and endocrinology, metabolism and diabetes; professor of physiology and biophysics; and Charles A. Boettcher II Chair in Atherosclerosis at the University of Colorado Denver Anschutz Medical Center, said in an interview. Eckel is also director of the lipid clinic at University of Colorado Hospital in Aurora.
Sessions of interest
The CMHC 2017 agenda focuses on four main sessions:
- Dyslipidemia, Atherosclerosis and CVD Risk Reduction;
- Lifestyle Management of CVD;
- Diabetes Management; and
- Hypertension, Cardio-Renal, HF.
Case discussions will be held within each session of the meeting and related posters will be on display in the exhibit hall.
Further, “there’s a lot of interaction with the panel and with the audience,” CMHC co-chair George L. Bakris, MD, professor of medicine and director of the ASH Comprehensive Hypertension Center at University of Chicago Medicine and Cardiology Today Editorial Board Member, said in an interview. “There’s ample time for one-on-one exchange with the faculty during the breaks.”
Cardiology Today Editorial Board Member Stanley L. Hazen, MD, PhD, chair of the department of cellular and molecular medicine, section head of preventive cardiology and rehabilitation, and director of the Center for Microbiome and Human Health at Cleveland Clinic, will present the main keynote session, titled Gut Microbes as a Participant and Therapeutic Target in Cardiometabolic Diseases.
“Dr. Hazen has carried out field-furthering research on the role of the gut microbiome on oxidative metabolism and atherosclerosis, building an exciting set of data that represent the importance of the microbiome, microbial metabolism and downstream effects on atherosclerotic cardiovascular disease,” Eckel said.
Other conference highlights include:
- An update on FDA decisions and approvals and late-breaking clinical trials over the past year on Oct. 5, with expert discussion from Bakris and Eckel, as well as Christie M. Ballantyne, MD, from Baylor College of Medicine; Jay S. Skyler, MD, from University of Miami; Cardiology Today Editorial Board Member Keith C. Ferdinand, MD, of Tulane University; and Cardiology Today’s Intervention Chief Medical Editor Deepak L. Bhatt, MD, MPH, of Brigham and Women’s Hospital and Harvard Medical School;
- Ballantyne will focus on treatment options for statin-intolerant patients with hypercholesterolemia on Oct. 5;
- Barbara Kahn, MD, of Beth Israel Deaconess Medical Center and Harvard Medical School, will discuss novel mechanisms associated with obesity and type 2 diabetes on Oct. 6;
- Frank A.J.L. Scheer, PhD, of Brigham and Women’s Hospital and Harvard Medical School, will focus on how the circadian rhythm affects obesity and CVD on Oct. 6;
- Kumar Sharma, MD, FAHA, of the University of California, San Diego, School of Medicine, will discuss kidney disease and metabolomics on Oct. 7; and
- David A. Calhoun, MD, of the University of Alabama at Birmingham, will discuss this year’s guideline updates on BP and resistant hypertension on Oct. 7.
Continued learning
“The goal of CMHC 2017 is for attendees to learn at least three new things, so when you go back to your office Monday and start seeing patients, you can implement them and improve patient care and outcomes,” Bakris said.
Cardiology Today and Healio.com will provide live coverage from CMHC 2017, including reports on the sessions described above and others, onsite video interviews and much more. For more information on the CMHC agenda and registration, visit www.cardiometabolichealth.org. – by Darlene Dobkowski
For more information:
George Bakris, MD, can be reached at gbakris@gmail.com.
Robert H. Eckel, MD, can be reached at robert.eckel@ucdenver.edu.
Disclosures: Bakris and Eckel are co-chairs of CMHC 2017.